Loading institutional data...
Loading institutional data...
Held by 303 of 5,944 reporting institutions (94th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $108.40 today, the market must believe free cash flow compounds 14.2%/yr for a decade (off $182M normalized FCF).
The market's 14.2% is in line with its 9-yr track record.
2-stage DCF · 0.05B shares · net debt $979M
mean 34.4% · volatility σ 74% · implied rate exceeded in 4/9 yrs
Central path = implied 14.2%/yr growth; shaded band = ±1σ (74%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-18
How a revenue dollar becomes profit — FY2026
Each value shows its share of revenue below it (common-size).
| Line Item | FY2026 | FY2025 | FY2024 | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 | FY2018 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.33B 100.0% | $1.36B 100.0% | $1.31B 100.0% | $1.17B 100.0% | $993.2M 100.0% | $870.5M 100.0% | $988.5M 100.0% | $967.6M 100.0% | $903.9M 100.0% | $886.1M 100.0% |
| Cost of Revenue | $546.4M 41.0% | $611.9M 45.0% | $617.5M 47.2% | $553.6M 47.4% | $487.7M 49.1% | $472.6M 54.3% | $504.0M 51.0% | $550.0M 56.8% | $492.0M 54.4% | $507.6M 57.3% |
| Cost of Products | — | — | — | — | — | — | — | — | $492.0M 54.4% | $507.6M 57.3% |
| Gross Profit | $787.6M 59.0% | $749.0M 55.0% | $691.5M 52.8% | $615.1M 52.6% | $505.5M 50.9% | $397.8M 45.7% | $484.5M 49.0% | $417.5M 43.2% | $411.9M 45.6% | $378.5M 42.7% |
| Research & Development | $59.8M 4.5% | $62.7M 4.6% | $54.4M 4.2% | $50.1M 4.3% | $46.8M 4.7% | $32.9M 3.8% | $30.9M 3.1% | $35.7M 3.7% | $39.2M 4.3% | $37.6M 4.2% |
| Selling, General & Admin | $442.4M 33.2% | $436.8M 32.1% | $429.8M 32.8% | $376.7M 32.2% | $340.1M 34.2% | $275.2M 31.6% | $282.0M 28.5% | $273.5M 28.3% | $316.5M 35.0% | $301.7M 34.1% |
| Total Operating Expenses | $630.9M 47.3% | $527.1M 38.7% | $526.7M 40.2% | $459.1M 39.3% | $424.8M 42.8% | $308.1M 35.4% | $381.2M 38.6% | $334.0M 34.5% | $355.8M 39.4% | $397.9M 44.9% |
| Operating Income | $156.7M 11.7% | $221.8M 16.3% | $164.9M 12.6% | $156.0M 13.4% | $80.8M 8.1% | $89.7M 10.3% | $103.4M 10.5% | $83.5M 8.6% | $56.2M 6.2% | -$19.4M -2.2% |
| Interest Expense | $19.3M 1.4% | $35.9M 2.6% | $19.5M 1.5% | $13.0M 1.1% | $5.8M 0.6% | $9.4M 1.1% | $13.5M 1.4% | $12.6M 1.3% | $7.7M 0.9% | — |
| Other Income (Expense), net | -$28.7M -2.2% | -$9.7M -0.7% | -$13.0M -1.0% | -$14.6M -1.3% | -$17.1M -1.7% | -$16.8M -1.9% | -$16.2M -1.6% | -$9.9M -1.0% | -$4.5M -0.5% | -$8.1M -0.9% |
| Pretax Income | $128.0M 9.6% | $212.1M 15.6% | $151.9M 11.6% | $141.4M 12.1% | $63.6M 6.4% | $72.9M 8.4% | $87.2M 8.8% | $73.6M 7.6% | $59.6M 6.6% | -$27.5M -3.1% |
| Income Tax Expense | $30.7M 2.3% | $44.4M 3.3% | $34.3M 2.6% | $26.0M 2.2% | $20.3M 2.0% | -$6.6M -0.8% | $10.6M 1.1% | $18.6M 1.9% | $14.1M 1.6% | -$1.2M -0.1% |
| Net Income | $97K 0.0% | $168K 0.0% | $117.6M 9.0% | $115.4M 9.9% | $43.4M 4.4% | $79.5M 9.1% | $76.5M 7.7% | $55.0M 5.7% | $45.6M 5.0% | -$26.3M -3.0% |
| Per Share | ||||||||||
| EPS (Basic) | $2.06 | $3.33 | $2.32 | $2.27 | $0.85 | $1.57 | $1.51 | $1.07 | $0.86 | $-0.51 |
| EPS (Diluted) | $2.05 | $3.31 | $2.29 | $2.24 | $0.84 | $1.55 | $1.48 | $1.04 | $0.85 | $-0.51 |
| Weighted Avg Shares (Basic) | 47.2M | 50.3M | 50.7M | 50.8M | 51.0M | 50.7M | 50.7M | 51.5M | 52.8M | 51.5M |
| Weighted Avg Shares (Diluted) | 47.4M | 50.7M | 51.4M | 51.4M | 51.4M | 51.3M | 51.8M | 52.9M | 53.5M | 51.5M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Insufficient balance-sheet detail (needs retained earnings, working capital, equity).
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $175M buybacks = $175M returned on $260M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Modest payoff on reinvested capital. Current ROIC on all capital: 5%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $245M covers the $8M due within a year 31.2× over. Scheduled principal only (excludes interest & revolver draws). As of 2026-03-28 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~1.6% on $1.2B of debt.
Cash of $245M fully covers short-term debt of $5M.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-18
Is the profit real, and how strong is the balance sheet?
FY2026 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 14.9× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2019 | FY2020 | FY2022 | FY2023 | FY2024 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 56.8 | 51.0 | 54.3 | 49.1 | 47.4 | 47.2 | 45.0 | 41.0 |
| Gross Profit | 43.2 | 49.0 | 45.7 | 50.9 | 52.6 | 52.8 | 55.0 | 59.0 |
| R&D | 3.7 | 3.1 | 3.8 | 4.7 | 4.3 | 4.2 | 4.6 | 4.5 |
| SG&A | 28.3 | 28.5 | 31.6 | 34.2 | 32.2 | 32.8 | 32.1 | 33.2 |
| Operating Income | 8.6 | 10.5 | 10.3 | 8.1 | 13.4 | 12.6 | 16.3 | 11.7 |
| Income Tax | 1.9 | 1.1 | -0.8 | 2.0 | 2.2 | 2.6 | 3.3 | 2.3 |
| Net Income | 5.7 | 7.7 | 9.1 | 4.4 | 9.9 | 9.0 | 0.0 | 0.0 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on HAE: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $829.3B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.0B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $466.9B | 111.8× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $367.5B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $341.5B | 28.5× | 19.8× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $245.6B | 36.7× | 31.7× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $207.8B | 27.1× | 17.8× | 5.7× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $186.3B | 22.1× | 20.3× | 6.3× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.6B | 27.6× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.2B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $149.7B | 41.9× | 30.9× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $139.7B | 50.0× | 38.4× | 13.9× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $129.1B | 33.2× | 28.3× | 10.8× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $128.3B | 18.2× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $117.9B | 24.7× | 12.5× | 3.2× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $112.9B | 63.9× | 11.3× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $105.2B | 32.8× | 18.1× | 4.2× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.0B | 22.8× | 16.1× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.1B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $90.7B | 16.3× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.1B | 18.9× | 19.6× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.5B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| HAE | $4.9B | 52.9× | 27.0× | 3.7× | -2.0% | 59.0% | 7.3% | 12.2% | 4.8% | 5.6× | 303 |
Peers = companies sharing HAE's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position